CA125-response assessment in epithelial ovarian cancer

✍ Scribed by D. J. Cruickshank; P. B. Terry; W. T. Fullerton

• Publisher: John Wiley and Sons
• Year: 1992
• Tongue: French
• Weight: 475 KB
• Volume: 51
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.2910510112

✦ Synopsis

To assess the clinical potential of serial serum CAI 25 measurements in the follow-up of patients with epithelial ovarian cancer, 74 consecutive unselected patients with histologically confirmed ovarian carcinoma were studied prospectively. There was an 83Oh concordance between clinical assessment and CAI 25 assessment of response. The positive predictive values of a rising CA I25 for disease progression and a falling CA I25 for disease regression were 0.93 and 0.94, respectively. The absolute CAI 25 values during observations of complete response (mean 96 U/ml; 95% confidence interval; 33 to 128 U/ml), partial response (mean 134 U/ml; 95% confidence interval; 98 to I59 U/ml) and stable or progressive disease (mean 39 I U/ml; 95% confidence interval; 282 to 545 U/ml) were significantly different. A randomized study is required to determine whether CAI25 monitoring has any benefit in terms of outcome, and particularly survival, in epithelial ovarian cancer.